Risperidone Tapering Schedule

Rationale for Dose Reduction

• Higher doses of risperidone (>6mg/day) are associated with increased risk of extrapyramidal side effects without additional therapeutic benefit 1

Recommended Tapering Schedule

• The American Academy of Child and Adolescent Psychiatry recommends beginning with a reduction from 6mg to 5.5mg daily and maintaining for 2-4 weeks, followed by 0.5mg reductions every 2-4 weeks until reaching the target dose of 4mg 2
• The entire tapering process may take 8-16 weeks to complete 2

Monitoring During Tapering

• Regular follow-up appointments (every 2-4 weeks) should be scheduled to assess for return of original symptoms that prompted risperidone treatment 2

Managing Potential Challenges

• If symptoms return or withdrawal symptoms occur during tapering, a more gradual taper with smaller dose reductions (0.25mg) may be considered 2
• Extending the time between dose reductions to 4-6 weeks may also be necessary 2

Important Considerations

• Developing a monitoring plan is critical as patients with psychiatric disorders may have a return of symptoms weeks to months after dose reduction 2
• Gradual tapering is prudent even if it's unclear whether the current medication is having a beneficial effect 2

Follow-up Plan

• Documenting baseline symptoms and functioning before initiating the taper is recommended 2
• Being prepared to adjust the tapering schedule based on the individual patient's response is necessary 2

Risperidone Tapering Guidelines

General Principles

• Abrupt discontinuation or major dose reduction of antipsychotics is considered unacceptable medical care and can lead to significant withdrawal symptoms, as stated by the Mayo Clinic Proceedings 3
• If withdrawal symptoms occur during tapering, consider temporarily returning to the previous dose and attempting a smaller reduction after symptoms stabilize, according to the Mayo Clinic Proceedings 3

Practical Implementation

• Monitor for withdrawal symptoms at each dose reduction, which may include insomnia, anxiety, irritability, or exacerbation of original symptoms, and consider temporarily returning to the previous dose if symptoms occur, as recommended by the Mayo Clinic Proceedings 3

Special Considerations

• Consider adjunctive medications to manage specific withdrawal symptoms if they occur, such as trazodone for insomnia, as suggested by the Mayo Clinic Proceedings 4

Monitoring During Tapering

• Schedule regular follow-up appointments to assess for withdrawal symptoms and potential relapse, and implement psychosocial support during the tapering process to help manage stress and anxiety that may accompany medication changes, as advised by the Mayo Clinic Proceedings 3

Tapering Antipsychotic Medications

Introduction to Cross-Tapering Protocol

• A slow, reasonable, collaborative taper with adjuvant treatments as needed for withdrawal symptoms is recommended by the Mayo Clinic Proceedings 5
• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, considers sudden cessation of antipsychotics unacceptable medical care, thus avoiding abrupt discontinuation of Latuda is crucial 6

Managing Transition and Potential Challenges

• If withdrawal symptoms occur during tapering, consider temporarily returning to the previous dose before attempting a more gradual reduction, as suggested by the Centers for Disease Control and Prevention, reported in MMWR Recommendations and Reports 6
• The Mayo Clinic Proceedings recommends that percentage reductions should not be understood as a straight-line taper; each new dose should be a percentage of the previous dose 5

Common Pitfalls to Avoid

• Abrupt discontinuation of Latuda can trigger withdrawal symptoms, according to the Centers for Disease Control and Prevention, reported in MMWR Recommendations and Reports 6
• "Cold referrals" to clinicians who have not agreed to accept the patient during medication transitions should be avoided, as stated by the Centers for Disease Control and Prevention, reported in MMWR Recommendations and Reports 6

Safe Tapering Plan for Latuda (Lurasidone)

Critical Safety Principles

• Never abruptly discontinue Latuda, as this can precipitate severe withdrawal symptoms and rapid mood destabilization, according to the Mayo Clinic Proceedings 7
• Patient agreement and collaboration are essential, ensuring the patient understands the plan, agrees with the pace, and knows they can request slower tapering if needed, as recommended by the Mayo Clinic Proceedings 7
• Do not abandon the patient if they struggle with the taper, consider pausing at a stable dose rather than pushing forward or discontinuing care, as advised by the Mayo Clinic Proceedings 7
• Do not use a fixed timeline, the taper must be adjusted based on the individual's response, not a predetermined schedule, according to the Mayo Clinic Proceedings 7
• Do not make "cold referrals" to other clinicians during the taper without ensuring they have agreed to accept the patient's care, as recommended by the Mayo Clinic Proceedings 7
• Ensure access to urgent psychiatric care if acute decompensation occurs during the taper, as suggested by the Mayo Clinic Proceedings 7

Latuda Tapering Schedule

Special Considerations

• Patients who have been on Latuda for years require much slower tapers than those on short-term therapy, with slow tapers potentially requiring several months or years and being more appropriate for patients who have been receiving prolonged treatment, as noted by the Mayo Clinic Proceedings 8

Guidelines on Benzodiazepine Use When Discontinuing Low‑Dose Aripiprazole

Assessment Considerations for Patients with Concurrent CNS Depressant Use

• In patients who are stopping a sub‑therapeutic dose of aripiprazole (2 mg daily), the presence of concurrent benzodiazepine or other central nervous system depressant use can complicate clinical assessment and may justify a slower, more gradual taper of aripiprazole. The Centers for Disease Control and Prevention (CDC) (MMWR Recommendations and Reports) note this as a factor to consider when planning discontinuation. 9

Prophylactic Benzodiazepine Prescribing

• The CDC (MMWR Recommendations and Reports) advises against the routine prophylactic prescription of benzodiazepines to pre‑empt anxiety during aripiprazole discontinuation, because doing so creates a new risk of benzodiazepine dependence without providing a pharmacologic benefit. 9